Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Matthew Link sold 20,734 shares of the company's stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $5.91, for a total transaction of $122,537.94. Following the sale, the insider now directly owns 726,838 shares in the company, valued at $4,295,612.58. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
Sight Sciences Stock Up 0.3 %
Shares of SGHT opened at $5.97 on Friday. The firm has a market cap of $297.04 million, a P/E ratio of -5.33 and a beta of 2.71. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.50 and a current ratio of 11.01. Sight Sciences, Inc. has a 52 week low of $1.04 and a 52 week high of $8.45. The firm's 50-day simple moving average is $6.31 and its 200 day simple moving average is $6.28.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.06. The company had revenue of $21.37 million for the quarter, compared to the consensus estimate of $21.32 million. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. During the same quarter in the prior year, the business earned ($0.30) earnings per share. On average, analysts forecast that Sight Sciences, Inc. will post -1 earnings per share for the current year.
Institutional Inflows and Outflows
Tim Sykes’ Urgent Trade Alert: “Make this move now”
From Timothy Sykes | Ad
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock
This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…
Click here to see a unique election-year trade
Several large investors have recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System bought a new stake in shares of Sight Sciences in the first quarter valued at about $59,000. Steele Capital Management Inc. acquired a new stake in Sight Sciences in the 2nd quarter worth about $67,000. SG Americas Securities LLC acquired a new stake in Sight Sciences in the 3rd quarter worth about $75,000. The Manufacturers Life Insurance Company bought a new stake in Sight Sciences in the 2nd quarter valued at about $95,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Sight Sciences by 51.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company's stock worth $141,000 after purchasing an additional 9,106 shares in the last quarter. Institutional investors own 55.51% of the company's stock.
Analyst Ratings Changes
Several research analysts have recently weighed in on the stock. Citigroup boosted their price objective on shares of Sight Sciences from $6.00 to $6.50 and gave the stock a "neutral" rating in a research note on Wednesday, July 10th. Lake Street Capital initiated coverage on Sight Sciences in a research report on Wednesday, August 21st. They set a "buy" rating and a $10.00 price target on the stock. Morgan Stanley raised their price objective on Sight Sciences from $5.40 to $6.50 and gave the company an "equal weight" rating in a research report on Monday, July 15th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research note on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $7.25.
Get Our Latest Report on Sight Sciences
About Sight Sciences
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
